Pharma supply chains under the microscope: raising revenue and cutting out counterfeiters

Pharmaceutical companies are paying more attention than ever before to their supply chains as they attempt to boost profits and clamp down on fake drugs, states a new report by health care industry analysts GBI Research.

The report examines the growing importance of strategic supply chain management in maximising revenue for global pharmaceutical companies, and how this is prompting the revision of traditional business models.

International pharmaceutical corporations are starting to tailor supply chains to products based on market demand and production costs. While manufacturing is commonly out-sourced to emerging economies where labor expenses are less substantial, branded products are produced closer to customer bases in developed countries as profit margins are higher and transportation costs lower.